MVP Investor Presentation 2020/21 Results **Gordon Naylor, Chair Brent MacGregor, CEO** 25 August 2021 Medical Developments International



Disclaimer

This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as 'believes', 'expects', 'anticipates', 'projects', 'intends', 'should', 'seeks', 'estimates', 'future' or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

- 1. pricing and product initiatives of competitors;
- 2. legislative and regulatory developments and economic conditions;
- 3. delay or inability in obtaining regulatory approvals or bringing products to market;
- 4. fluctuations in currency exchange rates and general financial market conditions;
- 5. uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;
- 6. increased government pricing pressures;
- 7. interruptions in production;
- 8. loss or inability to obtain adequate protection for intellectual property rights;
- 9. litigation;
- 10. loss of key executives or other employees; and
- 1. adverse publicity and news coverage.

There can be no assurance that any existing or future regulatory filings will satisfy any health authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales.

Should one or more of these risks or uncertainties materialise, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Medical Development International Limited is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.

Any statements regarding earnings is not a profit forecast and should not be interpreted to mean that Medical Developments International's earnings for this year or any subsequent period will necessarily match or exceed the historical published earnings of Medical Developments International. Medical Developments International Limited, its directors, officers and employees do not accept any liability whatsoever for any damage or loss caused by anything contained in this document.

For marketed products discussed in this presentation, please see full prescribing information on our website at www.medicaldev.com


All mentioned trademarks are legally protected.

A transitional year for MVP ... with COVID



FY21 STATUTORY FINANCIALS	\$M
Gross Revenue	25.7
Gross Margin \$	19.1
Net Profit After Tax	(12.6)
Cash on hand	36.3

Gross Revenue Bridge Europe Penthrox growth despite COVID



Overall gross revenue grew 9% over prior year...


... with much of this growth from contract income

Respiratory sales are lower – COVID-19 impact with late surge in FY20 buying, a milder cold and flu season and reduced community movement

Lower Penthrox sales – exiting distributor sold through stock

Modest growth in our Europe Penthrox business despite COVID-19 impact

EBIT Bridge Reflects the unique features of the year



Developments International COVID impact on our AU Penthrox and respiratory business

Suppressed Penthrox sales in Q2 due to distributor inventory sell-through

Modest growth of our Europe Penthrox

Result is an underlying EBIT of (\$4.4m)

\$9.0m of Impairments

\$9.5m of Penthrox EU transition costs

Positive impact of non-recurring contract income

5

Australian business is recovering from COVID Lockdowns are an ongoing challenge

Penthrox

Mundipharma Australia sell-through of inventory meant minimal sales for MVP in Q2

Once the sell-in period was over, and MVP in full control, we witnessed a rapid recovery of our business through the end of FY21

Our H2 FY21 sales were the highest ever in-market for a six-month period

Respiratory

COVID-related panic buying in late FY20 led to slow start to FY21, compounded by a depressed market

Recovery began in March, driven by anti-static Breath-a-Tech spacer into Chemist Warehouse

Upcoming launch of our collapsible spacer into Chemist Warehouse should generate further encouraging signs, but the lockdowns will impact our recovery




Penthrox sales showing growth again in Europe, driven by the UK & France

Improving COVID environment

Increased access to hospitals

~14,000 units sold in July, highest ever Launch of Penthrox across Nordic region Distributors are keen to expand territory



In-market unit sales (3-month moving average)

The UK market is approaching a new threshold

Medical Developments International

Increased growth since May 2020

June saw the highest ever month for UK hospital sales

UK passing 6000 unit per month

Birmingham Hospital study being marketed as tool to engage key hospitals

Both national Pre- and Hospital guidelines now include Penthrox

8000 7000 6000 5000 4000 3000 2000 1000 С September 2017 March 2010 November 201' M342012 14142012 November 202 January 2022 inber 2012 anuary201 -ember 2012 ,ember 2012 3nuary 202 amber 201 Narch 201. May 201. 1414202 Narch 202 May 202 JUNY 202 March 202 Narch 201

In-market unit sales (3-month moving average)


The current trend in France is encouraging

Highest sales since July 2019

Currently 1 Key Account Manager (KAM) since March; 8 more to join in September

Principal investigator of seminal French study to train our KAMs

Key success factor will be focus!



Advancing our plans for longer-term growth

Penthrox – US

Following guidance from the FDA in April, we have worked with an advisory group to revise our clinical trial protocol

We intend to submit revised protocol to FDA in November; we expect an answer within 30 days

Penthrox – China

Developments Internationa

MVP has achieved ethics approval for its required Pharmacokinetic study, with the first patient to be enrolled in Q4 2021

The two required additional studies, trauma and minor surgical procedure, begin enrolment in early 2022

Next generation device development

Entering final engineering stage of the new device, including an enhanced container closure system

Anticipate launch of next gen Penthrox in Australia by FY24, with Europe and US to follow one year later

Flow technology

Lidocaine has successfully advanced to 'Stage 4' commercial scale production capability

We will conduct a strategy review of Flow technology with the Board to determine our desired commercial path forward

Other Penthrox indications

We are exploring broader indications for Penthrox to expand our addressable market

consideration under include Targets expansion to paediatric age, short surgeries pain management, e.g. biopsies

We are building a global company

FY21 progress

Commercial Operations overhaul in Australia, and in Europe

Medical Affairs focus to support commercial execution

Renewed Human Resources capability

Clinical Development accountability and clarity

Identify Key decision-making processes and platforms to support global aspiration



FY22 enhancements

Further changes in AU; augmentation of Europe team, based on Germany and Italy outcomes

Further expansion of Medical Affairs resources in Europe and at global HQ

Overhaul of talent management processes

Hire of Head of Clinical Development

Revamp S&OP, new product development, strategic planning, capital project review, ERP

MVP is preparing for growth



Medical Developments International

The market potential for Penthrox remains strong

The first transformational changes are done ... more changes will roll out this year

Early signs in France are encouraging ... and 8 new KAMs are beginning in September

Both of our partners in Europe want to expand their territories

We have set aggressive goals for FY22 and beyond



Chelsea's Hakim Ziyech, being treated with the Green Whistle during UEFA Super Cup in Belfast, August 2021

only rsonal use